- Home
- ARMP vs ABOS Comparison
ARMP vs ABOS Comparison
Compare ARMP & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARMP
- ABOS
- Stock Information
- Founded
- ARMP N/A
- ABOS 1996
- Country
- ARMP United States
- ABOS United States
- Employees
- ARMP N/A
- ABOS N/A
- Industry
- ARMP Biotechnology: Biological Products (No Diagnostic Substances)
- ABOS Biotechnology: Pharmaceutical Preparations
- Sector
- ARMP Health Care
- ABOS Health Care
- Exchange
- ARMP Nasdaq
- ABOS Nasdaq
- Market Cap
- ARMP 52.1M
- ABOS 60.6M
- IPO Year
- ARMP N/A
- ABOS 2021
- Fundamental
- Price
- ARMP $1.91
- ABOS $1.20
- Analyst Decision
- ARMP Strong Buy
- ABOS Strong Buy
- Analyst Count
- ARMP 1
- ABOS 4
- Target Price
- ARMP $9.00
- ABOS $6.50
- AVG Volume (30 Days)
- ARMP 36.4K
- ABOS 304.2K
- Earning Date
- ARMP 08-12-2025
- ABOS 08-12-2025
- Dividend Yield
- ARMP N/A
- ABOS N/A
- EPS Growth
- ARMP N/A
- ABOS N/A
- EPS
- ARMP N/A
- ABOS N/A
- Revenue
- ARMP $4,699,000.00
- ABOS N/A
- Revenue This Year
- ARMP $8.43
- ABOS N/A
- Revenue Next Year
- ARMP N/A
- ABOS N/A
- P/E Ratio
- ARMP N/A
- ABOS N/A
- Revenue Growth
- ARMP 14.24
- ABOS N/A
- 52 Week Low
- ARMP $0.90
- ABOS $0.86
- 52 Week High
- ARMP $3.42
- ABOS $3.60
- Technical
- Relative Strength Index (RSI)
- ARMP 52.83
- ABOS 53.50
- Support Level
- ARMP $1.74
- ABOS $1.05
- Resistance Level
- ARMP $2.00
- ABOS $1.31
- Average True Range (ATR)
- ARMP 0.15
- ABOS 0.09
- MACD
- ARMP -0.03
- ABOS 0.01
- Stochastic Oscillator
- ARMP 43.59
- ABOS 48.61
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.